Loading...
XSHE300463
Market cap1.02bUSD
Jan 14, Last price  
12.65CNY
1D
3.10%
1Q
-8.73%
Jan 2017
-48.47%
IPO
-14.31%
Name

Maccura Biotechnology Co Ltd

Chart & Performance

D1W1MN
XSHE:300463 chart
P/E
23.96
P/S
2.59
EPS
0.53
Div Yield, %
3.27%
Shrs. gr., 5y
2.05%
Rev. gr., 5y
1.52%
Revenues
2.90b
-19.75%
521,308,317606,154,698779,426,579934,846,0801,065,169,0321,488,780,8841,969,983,7292,685,304,9463,222,956,0193,703,877,0063,980,647,1833,608,411,8952,895,769,512
Net income
313m
-55.86%
120,415,498158,209,363193,155,928226,210,932251,043,594312,022,756374,132,214444,928,508525,262,640793,917,986956,604,404708,180,360312,618,556
CFO
912m
+8.17%
85,546,596110,959,27298,392,339115,090,08433,183,26349,315,14779,033,594193,905,904459,516,3111,094,048,8101,616,683,215843,216,884912,088,535
Dividend
Jul 03, 20240.15402 CNY/sh
Earnings
Jun 03, 2025

Profile

Maccura Biotechnology Co.Ltd engages in the research, development, manufacture, and sale of IVD products and related services in China and internationally. The company offers immunoassay products, such as chemiluminescence analyzers and reagents; clinical chemistry reagents for hepatic function, glycometabolism, iron and other, renal function, coagulation, special protein, cardiac, and lipids; and clinical laboratory products, such as automatic hematology, and automatic and semi-automatic coagulation analyzers. It also provides SARS-COV-2(COVID-19) products that includes nucleic acid detection kit and other products; glucometers; POCT products, such as fluorescence immunoassay analyzers, as well as colloidal gold kits; molecular diagnosis products, such as PCR kit; and pathology products. The company was incorporated in 1994 and is based in Chengdu, China.
URL
http://www.maccura.com/
IPO date
May 28, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,895,770
-19.75%
3,608,412
-9.35%
Cost of revenue
2,048,560
2,599,117
Unusual Expense (Income)
NOPBT
847,209
1,009,295
NOPBT Margin
29.26%
27.97%
Operating Taxes
690
87,687
Tax Rate
0.08%
8.69%
NOPAT
846,520
921,609
Net income
312,619
-55.86%
708,180
-25.97%
Dividends
(244,643)
(286,636)
Dividend yield
2.65%
2.73%
Proceeds from repurchase of equity
(406)
BB yield
0.00%
Debt
Debt current
144,647
400,380
Long-term debt
188,456
315,880
Deferred revenue
28,802
31,074
Other long-term liabilities
3,829
1
Net debt
(675,579)
(534,804)
Cash flow
Cash from operating activities
912,089
843,217
CAPEX
(877,905)
Cash from investing activities
(513,621)
Cash from financing activities
(152,751)
930,049
FCF
1,081,217
239,200
Balance
Cash
1,147,102
1,251,064
Long term investments
(138,419)
Excess cash
863,894
1,070,643
Stockholders' equity
4,679,526
4,918,878
Invested Capital
6,100,324
6,127,830
ROIC
13.85%
16.61%
ROCE
11.86%
13.61%
EV
Common stock shares outstanding
612,497
607,789
Price
15.07
-12.89%
17.30
-40.73%
Market cap
9,230,333
-12.22%
10,514,743
-35.31%
EV
8,781,390
10,216,330
EBITDA
1,165,032
1,279,494
EV/EBITDA
7.54
7.98
Interest
34,451
35,056
Interest/NOPBT
4.07%
3.47%